Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: Gurupup who wrote (1402)	3/17/1998 3:31:00 PM
From: Gurupup	Read Replies (1) \| Respond to of 5736

I am taking the liberty of posting some of the responses I have received from lurkers, who also happen to be in the medical profession, and I thought they might be of interest. Quick comment regarding the e-mail you have received from physicians: In my opinion, the need to monitor bilirubin levels in newborns who are jaundiced will always be there. We need to monitor more than once daily on those that are close to dangerous levels, but we are always reluctant for extra heel pricks and lab time. This is a definite market. Once you know if hyperbilirubinemia is conjugated or unconjugated, you don't continue to fractionate it even when drawing blood. You follow the total bilirubin because it is faster, cheaper, and tells you which direction you are headed. This will not limit the ccsi device in it's role to monitor elevated levels. There are also adult patients in the ICU who need bili levels monitored closely, but this is a much smaller market, probably insignificant compared to the newborns. I also don't think that having the same DRG or diagnostic code used when ordering the test has anything to do with expected reimbursement rates. If we can beat blood sticks on the basis of labor cost alone, I think even a slightly higher cost for new technology replacing manhours would be expected. This is America. If we have the cheapest test (based on true cost-based accounting including manhours), then we get to charge more. When this stops, there will be no new technology introduced. Just my opinions, but food for thought. By the way, why in the hell would new (or old) short sellers jump in so strong today when we are expecting to hear good news soon.